The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Current and future treatment strategies for CLL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, outlines current and future treatment strategies for chronic lymphocytic leukemia (CLL), commenting on the move away from chemotherapy and towards more targeted agents in the frontline setting. In particular, Dr Patel talks on options for patients who have relapsed on both a BTK inhibitor and a BCL-2 inhibitor. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
